– Acquisition extends Glooko’s diabetes digital health platform into hospitals, creating a comprehensive inpatient-to-outpatient diabetes management connected care solution –
– Deal underscores Glooko’s commitment to accelerating growth and innovation in diabetes care –
PALO ALTO, Calif.–(BUSINESS WIRE)–Glooko, Inc., a leading provider of remote patient monitoring and digital health solutions for diabetes, today announced that it has acquired Monarch Medical Technologies, the developer of the EndoTool® Glucose Management System. EndoTool is an industry-leading software platform for inpatient insulin dosing and glycemic management. This strategic acquisition expands Glooko’s connected care capabilities into inpatient glycemic management, complementing its strong foundation in outpatient diabetes management and shaping the future of a single, integrated solution that will support patients and clinicians across the full continuum of care.
“This acquisition represents a pivotal step in Glooko’s mission to transform diabetes management in every care setting,” said Mike Alvarez, Chief Executive Officer of Glooko. “We’ve built a strong foundation in the outpatient space — simplifying diabetes management for clinicians through unified device integration, EHR connectivity, and actionable insights. By adding Monarch’s proven inpatient insulin dosing expertise, we’re now uniquely positioned to deliver a truly comprehensive hospital-to-home solution that can improve outcomes, streamline workflows, and enhance patient safety. Looking ahead, this platform also creates opportunities to extend our leadership into primary care and advanced glycemic management, enabling us to serve patients and providers across the full continuum of care.”
Inpatient glycemic management is vital to patient safety, outcomes, and hospital performance, with 30–40% of hospitalized patients requiring insulin therapy to maintain acceptable glucose control.1 Poor glucose management can lead to serious complications, longer stays, and higher costs. EndoTool, an FDA-cleared software platform that assists clinicians in optimizing insulin dosing for hospitalized patients, uses a patented, patient-specific algorithm to deliver precise, guideline-aligned insulin dosing in real time, reducing the risk of hypoglycemia and helping hospitals meet CMS quality measures while streamlining clinical workflows.
“Effective glycemic management doesn’t begin or end at the hospital doors. It’s a continuous journey,” said Mark Clements, M.D., Ph.D., Chief Medical and Strategy Officer at Glooko. “With new CMS quality measures and HEDIS metrics driving the need for consistent glucose control, connected solutions are no longer optional, they’re essential. By integrating EndoTool with Glooko’s outpatient platform, we believe we will be better able to ensure safer care transitions for people with diabetes, help hospitals meet quality and regulatory requirements, and deliver measurable improvements in patient outcomes across the continuum.”
The acquisition of Monarch Medical advances Glooko’s strategic focus on connected care in diabetes management. Glooko’s platform, used by millions of patients and more than 8,000 clinics worldwide, aggregates data from more than 200 connected devices – including blood glucose meters, insulin pumps, continuous glucose monitors (CGMs), and others – to make diabetes management easier for endocrinologists, primary care providers, nurses, diabetes educators, dietitians, and other clinicians by unifying data from a variety of devices onto a single platform, integrating smoothly with EHR workflows, and delivering actionable insights. By adding EndoTool to its platform, Glooko will support acute care settings with precision insulin dosing algorithms, and continue to support those patients post-discharge via its remote monitoring tools. This integrated approach aims to reduce hospital readmissions, enhance continuity of care, and improve overall glycemic control across settings.
The combined company will maintain all current offerings and support for both Glooko and EndoTool customers. In the near term, Glooko and Monarch Medical will continue to operate their products as they do today, ensuring no disruption for users. Longterm, Glooko plans to integrate both offerings on a single platform.
Building on Strong Investor Backing
This acquisition follows Glooko’s $100 million Series F financing round completed in October 2024, led by Georgian with participation from Canaan Partners, Health Catalyst Capital, Mayo Ventures, Realization Capital Partners and other strategic investors. At that time, Glooko outlined its intent to accelerate growth through both product innovation and selective acquisitions. The addition of Monarch Medical demonstrates how that capital and investor support are fueling Glooko’s strategy to expand its connected care platform, extend its reach into new care settings, and solidify its position as a global leader in digital health for diabetes management.
Terms of the acquisition are not being disclosed.
About Glooko
Glooko is focused on improving health outcomes for people with diabetes through our personalized, intelligent, connected care platform. Our proven technologies strengthen connections between patients and providers, drive patient engagement and adherence via digital therapeutics, with more than 4.4 million people around the world who have used the Glooko platform. By seamlessly integrating with electronic health records (EHRs), providing a unified device ecosystem, and delivering actionable insights, Glooko aims to enhance clinical workflows and improve outcomes for people with diabetes and their care providers. For more information, please visit www.glooko.com.
About Monarch Medical Technologies
Monarch Medical is the Charlotte, NC-based maker of the EndoTool Glucose Management System, a leading enterprise solution for inpatient glycemic control. Founded by clinicians, Monarch’s mission is to improve patient safety and outcomes through precise insulin dosing technology. The EndoTool platform has been adopted by hospitals and health systems across the United States to standardize and optimize insulin therapy, virtually eliminating severe hypoglycemia and reducing hyperglycemia in critical care settings. For more information, visit www.monarchmedtech.com.
1 Rushakoff RJ, Sullivan MM, MacMaster HW, et al. Association between a virtual glucose management service and glycemic control in hospitalized adult patients: an observational study. Ann Intern Med 2017;166:621–627
Contacts
Media Contact
Julia Fuller
(858) 692-2001
[email protected]
